SBMF Online Payment ▶

test directorySearch Results

Click here to search again.

Test Name:
Hepatocellular Carcinoma Tumor Marker Panel


  • SBMF No:
    44744
  • Performance Lab Name:
    ARUP Laboratories
  • Test Mnemonic:
    HEP CAR
  • ABN:
    Not required
  • CPT Code:
    82107; 83951
  • Ref Lab Test No:
    0081326
  • Test Includes:
    Alpha Fetoprotein, Total
    Alpha Fetoprotein, L3 Percent
    Des-gamma-carboxy Prothrombin
  • Also Known As:
    HCC Tumor Marker Panel
  • Also See:
    44743 Alpha Fetoprotein, Total & L3 Percent
    44742 Des-gamma-carboxy Prothrombin
  • Spec Type:
    Serum
  • Spec Container:
    Red top (serum) or gold top (SST) tube
  • Pref Vol:
    1.0 mL
  • Min Vol:
    0.5 mL
  • Fasting:
    No
  • Spec Collect:
    Routine venipuncture
  • Spec Process:
    Clot 30 minutes
    Promptly centrifuge 15 minutes
    Immediately transfer serum to separate plastic tube
  • Spec Store Transport:
    Refrigerated
  • Spec Stability:
    After separation from cells:
    8 hours room temperature (20-30°C)
    5 days refrigerated (2-8°C)
    3 months frozen (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles
  • Spec Reject:
    Plasma specimen
  • Spec Remarks:
    Separate serum from cells ASAP or within 2 hours of collection
  • Methodology:
    Quantitative Liquid-Phase Binding Immunoassay
  • Clinical Significance:
    Refer to:
    ARUP Consult | The Physician's Guide to Laboratory Test Selection and Interpretation
  • Reference Range:

    By report

    Interpretive Data:
    The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.

    The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.
    Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. For pregnant females, the result is not interpretable as a tumor marker.

    The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma.

  • Day Run:
    AFP L3%: Thu
    DCP: Tue
  • Time Reported:
    4-7 days
  • Test Type:
    TUMOR MARKER

Home > Test Directory > Search Results

Test Directory